Hepatobiliary and Pancreatic Neoplasms: Biomarkers and Targeted Therapy

Dear Colleagues,

Hepatobiliary and pancreatic neoplasms, including hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and pancreatic ductal adenocarcinoma (PDAC), are lethal malignancies. They are often diagnosed at advanced stages, and their currently available therapeutics are unsatisfactory and not curative. Several molecular targeted agents and immune checkpoint inhibitors have been recently used in clinic, but no patient stratification strategy exists for these drugs due to a lack of predictive biomarkers for their efficacy. In addition, even after the cancer genome sequence era, their molecular pathogenesis is not fully elucidated, and further basic and translational research is desired to identify novel therapeutic targets for these deadly diseases.

For this Special Issue of Cancers, we welcome original research and review articles that focus on recent advances in the area of hepatobiliary and pancreatic cancer research.

Potential subjects include but are not limited to the following:

• Therapeutic or diagnostic biomarkers for hepatobiliary and pancreatic neoplasms;
• Targeted therapies for hepatobiliary and pancreatic neoplasms;
• Molecular pathogenesis of hepatobiliary and pancreatic neoplasms.

Dr. Takahiro Kodama
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.